PMID- 34877325
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211211
IS  - 2307-8960 (Print)
IS  - 2307-8960 (Electronic)
IS  - 2307-8960 (Linking)
VI  - 9
IP  - 32
DP  - 2021 Nov 16
TI  - Efficacy of Yiqi Jianpi anti-cancer prescription combined with chemotherapy in 
      patients with colorectal cancer after operation.
PG  - 9869-9877
LID - 10.12998/wjcc.v9.i32.9869 [doi]
AB  - BACKGROUND: At present, colorectal cancer is routinely treated with adjuvant 
      radiotherapy and chemotherapy postoperatively. The adverse effects (AEs) of 
      chemotherapy usually interrupt the treatment of chemotherapy. Traditional Chinese 
      medicine (TCM) has demonstrated great potential in improving patients' clinical 
      symptoms, regulating the immune function, improving the life quality, and 
      reducing the AEs of chemotherapy. AIM: To observe the clinical efficacy of Yiqi 
      Jianpi anti-cancer prescription combined with chemotherapy in patients with 
      colorectal cancer after operation. METHODS: Data from patients diagnosed with 
      colorectal cancer between January 2019 and February 2021 were collected from 
      Liaoning Cancer Hospital and Institute and the Second Affiliated Hospital of 
      Liaoning University of Traditional Chinese Medicine. Patients receiving the 
      chemotherapy regimen of capecitabine plus oxaliplatin (CAPOX) after radical 
      resection of colorectal cancer were prospectively collected and randomly divided 
      into an experimental group and a control group. The experimental group was given 
      Yiqi Jianpi anti-cancer prescription combined with the CAPOX regimen, while the 
      control group was given the CAPOX regimen alone. After six cycles of 
      chemotherapy, the scores of TCM symptoms, Karnofsky performance scale (KPS) 
      score, levels of T-cell subsets, and AEs after chemotherapy of the two groups 
      were compared. RESULTS: A total of 70 patients were randomly divided into either 
      an experimental group (n = 35, no dropout) or a control group (n = 33, with 2 
      dropouts). Compared with the control group, the experimental group improved 
      significantly (P < 0.05) in scores of TCM symptoms, KPS score, levels of T-cell 
      subsets, and AEs of chemotherapy. CONCLUSION: Yiqi Jianpi anti-cancer 
      prescription can effectively improve spleen deficiency, regulate the immune 
      function, and alleviate the AEs of chemotherapy, so as to improve the life 
      quality of patients with good therapeutic effects and application prospect in 
      clinical practice.
CI  - (c)The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights 
      reserved.
FAU - Li, Zheng
AU  - Li Z
AD  - Graduate School, Liaoning University of Traditional Chinese Medicine, Shenyang 
      110847, Liaoning Province, China.
FAU - Yin, Dong-Feng
AU  - Yin DF
AD  - Oncology Department, The Affiliated Hospital of Liaoning University of 
      Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China. 
      148003642@qq.com.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Integrated Traditional Chinese and Western Medicine, Liaoning 
      Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China.
FAU - Zhang, Xin-Wei
AU  - Zhang XW
AD  - Department of Integrated Traditional Chinese and Western Medicine, Liaoning 
      Cancer Hospital and Institute, Shenyang 110042, Liaoning Province, China.
FAU - Zhou, Li-Jiang
AU  - Zhou LJ
AD  - Oncology Department, The Affiliated Hospital of Liaoning University of 
      Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China.
FAU - Yang, Jun
AU  - Yang J
AD  - Oncology Department, The Affiliated Hospital of Liaoning University of 
      Traditional Chinese Medicine, Shenyang 110032, Liaoning Province, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - World J Clin Cases
JT  - World journal of clinical cases
JID - 101618806
PMC - PMC8610922
OTO - NOTNLM
OT  - Adverse effects
OT  - Anti-cancer
OT  - Chemotherapy
OT  - Immune function
OT  - Life quality
OT  - Postoperative colorectal cancer
OT  - Yiqi Jianpi
COIS- Conflict-of-interest statement: There is no conflict of interest to disclose.
EDAT- 2021/12/09 06:00
MHDA- 2021/12/09 06:01
PMCR- 2021/11/16
CRDT- 2021/12/08 06:32
PHST- 2021/06/22 00:00 [received]
PHST- 2021/07/16 00:00 [revised]
PHST- 2021/08/25 00:00 [accepted]
PHST- 2021/12/08 06:32 [entrez]
PHST- 2021/12/09 06:00 [pubmed]
PHST- 2021/12/09 06:01 [medline]
PHST- 2021/11/16 00:00 [pmc-release]
AID - 10.12998/wjcc.v9.i32.9869 [doi]
PST - ppublish
SO  - World J Clin Cases. 2021 Nov 16;9(32):9869-9877. doi: 10.12998/wjcc.v9.i32.9869.